Alto Neuroscience, Inc. (ANRO) Quarterly EPS earnings growth

Alto Neuro - graphic logo of issuer ANRO

Expansion risks for the Alto Neuroscience, Inc. (ANRO) pipeline and the battle for pharmaceutical market share are evident through the quarterly EPS growth efficiency metric on the GURU.Markets chart, where -3.20 determines the current status of the parameter. Personalized therapy selection via biomarkers creates a unique ecosystem, while the professional leadership of Amit Etkin ensures the precise execution of R&D plans powered by the AI platform.

Alto Neuroscience (ANRO) - Year-over-year earnings per one share growth for the last 12 months from 02/21/2024 to 11/16/2026

ANRO (altoneuroscience.com): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental valuation:Alto Neuroscience, ANRO
Flagship merchandise of Alto Neuroscience, Inc.

Quarterly EPS growth measures the efficiency of converting market activity into net profit per share, allowing for an assessment of the business's fundamental stability and capitalization rates. By analyzing changes in quarterly EPS dynamics, an investor can see how the implementation of AI and biomarkers in precision psychiatry at Alto Neuroscience, Inc. (ANRO) transforms technological advantage into tangible financial results for shareholders.

Competitor analysis for Alto Neuroscience, Inc.

ALKS (alkermes.com) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharma (AVDL)|ATAI (atai.life) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months GH Research PLC (GHRS)|Quarterly EPS earnings growth MNMD|CMPS (COMPASS Pathways PLC) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months lbpharma.us LBRX|Bright Minds Biosciences Inc (DRUG) - Earnings per share growth in annualized terms for the last twelve months|VNDA: Year-over-year net earnings per share growth for the last 12 months|Cybin Inc (CYBN) - Year-over-year net earnings per share growth for the last 12 months|NRx Pharmaceuticals, Inc. (NRXP) - Year-over-year earnings per share growth for the last twelve months|CING - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Silo Pharma, Inc.|chinapharmaholdings.com (CPHI) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth CMND|Psyence Biomedical Ltd. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|Seelos Therapeutics Inc. (SEEL) - Earnings per share growth in annualized terms for the last twelve months|VRPX: Year-over-year net earnings per share growth for the last 12 months|KRTX - Quarterly EPS earnings growth